Publications

  1. Dispenzieri A, Buadi F, Kumar SK, Reeder CB, Sher T, Lacy MQ, Kyle RA, Mikhael JR, Roy V, Leung N, Grogan M, Kapoor P, Lust JA, Dingli D, Go RS, Hwa YL, Hayman SR, Fonseca R, Ailawadhi S, Bergsagel PL, Chanan-Khan A, Rajkumar SV, Russell SJ, Stewart K, Zeldenrust SR, Gertz MA. Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. Mayo Clin Proc. 2015 Aug; 90(8):1054-81.
    View PubMed
  2. Gupta E, Finn L, Johns G, Pruthi RK, Roy V. Correction of factor XI deficiency by liver transplantation. Blood Coagul Fibrinolysis. 2015 Jul 20.
    View PubMed
  3. Russell A, Malik S, Litzow M, Gastineau D, Roy V, Zubair AC. Dual roles of autologous CD8+ T cells in hematopoietic progenitor cell mobilization and engraftment. Transfusion. 2015 Jul; 55(7):1758-65. Epub 2015 Mar 11
    View PubMed
  4. Vij R, Kumar S, Zhang MJ, Zhong X, Huang J, Dispenzieri A, Abidi MH, Bird JM, Freytes CO, Gale RP, Kindwall-Keller TL, Kyle RA, Landsburg DJ, Lazarus HM, Munker R, Roy V, Sharma M, Vogl DT, Wirk B, Hari PN. Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant. 2015 Feb; 21(2):335-41. Epub 2014 Nov 01.
    View PubMed
  5. Kumar SK, LaPlant B, Chng WJ, Zonder J, Callander N, Fonseca R, Fruth B, Roy V, Erlichman C, Stewart AK, Mayo Phase 2 Consortium. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood. 2015 Jan 15; 125(3):443-8. Epub 2014 Nov 13.
    View PubMed
  6. Kumar SK, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA, Laumann K, Thompson MA, Witzig TE, Buadi FK, Rivera CE, Mikhael JR, Bergsagel PL, Kapoor P, Hwa L, Fonseca R, Stewart AK, Chanan-Khan A, Rajkumar SV, Dispenzieri A. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J. 2015; 4:e338. Epub 2015 Aug 14.
    View PubMed
  7. Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Di Bacco A, Estevam J, Gupta N, Hui AM, Rajkumar V, Richardson PG. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol. 2014 Dec; 15(13):1503-12. Epub 2014 Nov 14.
    View PubMed
  8. Sharma M, Zhang MJ, Zhong X, Abidi MH, Akpek G, Bacher U, Callander NS, Dispenzieri A, Freytes CO, Fung HC, Gale RP, Gasparetto C, Gibson J, Holmberg LA, Kindwall-Keller TL, Klumpp TR, Krishnan AY, Landau HJ, Lazarus HM, Lonial S, Maiolino A, Marks DI, Mehta P, Mikhael Med Jr, Nishihori T, Olsson R, Ramanathan M, Roy V, Savani BN, Schouten HC, Scott E, Tay J, To LB, Vesole DH, Vogl DT, Hari P. Older patients with myeloma derive similar benefit from autologous transplantation. Biol Blood Marrow Transplant. 2014 Nov; 20(11):1796-803. Epub 2014 Jul 18.
    View PubMed
  9. Khera N, Chang YH, Hashmi S, Slack J, Beebe T, Roy V, Noel P, Fauble V, Sproat L, Tilburt J, Leis JF, Mikhael J. Financial burden in recipients of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014 Sep; 20(9):1375-81. Epub 2014 May 24.
    View PubMed
  10. Paulus A, Masood A, Miller KC, Khan AN, Akhtar D, Advani P, Foran J, Rivera C, Roy V, Colon-Otero G, Chitta K, Chanan-Khan A. The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs. Br J Haematol. 2014 Apr; 165(1):78-88. Epub 2014 Jan 27
    View PubMed
  11. Paulus A, Chitta K, Akhtar S, Personett D, Miller KC, Thompson KJ, Carr J, Kumar S, Roy V, Ansell SM, Mikhael JR, Dispenzieri A, Reeder CB, Rivera CE, Foran J, Chanan-Khan A. AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenstrom macroglobulinaemia. Br J Haematol. 2014 Feb; 164(3):352-65. Epub 2013 Nov 17.
    View PubMed
  12. Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R, Kapoor P, Bergsagel PL, McCurdy A, Gertz MA, Lacy MQ, Lust JA, Russell SJ, Zeldenrust SR, Reeder C, Roy V, Buadi F, Dingli D, Hayman SR, Leung N, Lin Y, Mikhael J, Kumar SK. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood. 2013 Dec 19; 122(26):4172-81. Epub 2013 Oct 21.
    View PubMed
  13. Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn JY, Costa LJ, de Lima M, Gale RP, Hale GA, Halter J, Hamadani M, Inamoto Y, Kamble RT, Litzow MR, Loren AW, Marks DI, Olavarria E, Roy V, Sabloff M, Savani BN, Seftel M, Schouten HC, Ustun C, Waller EK, Weisdorf DJ, Wirk B, Horowitz MM, Arora M, Szer J, Cortes J, Kalaycio ME, Maziarz RT, Saber W. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013 Dec 5; 122(24):3863-70. Epub 2013 Sep 24.
    View PubMed
  14. Roy V, Pockaj BA, Allred JB, Apsey H, Northfelt DW, Nikcevich D, Mattar B, Perez EA. A Phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG study N0338. Am J Clin Oncol. 2013 Dec; 36(6):540-4.
    View PubMed
  15. Larsen JT, Hogan WJ, Micallef IN, Dispenzieri A, Gertz MA, Inwards DJ, Tun HW, Roy V, Geyer SM, Allred JB, Wu W, Ansell SM, Elliott MA, Tefferi A, Porrata LF, Gastineau DA, Lacy MQ, Litzow MR. A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin. Leuk Lymphoma. 2013 Aug; 54(8):1713-8. Epub 2012 Dec 31.
    View PubMed
  16. Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, Kumar S, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Nishihori T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobadi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA, Landau H, Schouten HC, Maziarz RT, Michael J, Kindwall-Keller T, Stiff PJ, Gibson J, Lonial S, Krishnan A, Disp Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant. 2013 May; 19(5):760-6. Epub 2013 Jan 5
    View PubMed
  17. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A, Lacy MQ, Mayo Clinic. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013 Apr; 88(4):360-76.
    View PubMed
  18. Andhavarapu S, Roy V. Immunomodulatory drugs in multiple myeloma. Expert Rev Hematol. 2013 Feb; 6(1):69-82.
    View PubMed
  19. Witzig TE, Laumann KM, Lacy MQ, Hayman SR, Dispenzieri A, Kumar S, Reeder CB, Roy V, Lust JA, Gertz MA, Greipp PR, Hassoun H, Mandrekar SJ, Rajkumar SV. A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia. 2013 Jan; 27(1):220-5. Epub 2012 Aug 20.
    View PubMed
  20. Dispenzieri A, Buadi F, Laumann K, LaPlant B, Hayman SR, Kumar SK, Dingli D, Zeldenrust SR, Mikhael JR, Hall R, Rajkumar SV, Reeder C, Fonseca R, Bergsagel PL, Stewart AK, Roy V, Witzig TE, Lust JA, Russell SJ, Gertz MA, Lacy MQ. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood. 2012 Jun 7; 119(23):5397-404. Epub 2012 Apr 04.
    View PubMed
  21. Kumar SK, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA, Allred J, Laumann KM, Bergsagel LP, Dingli D, Mikhael JR, Reeder CB, Stewart AK, Zeldenrust SR, Greipp PR, Lust JA, Fonseca R, Russell SJ, Rajkumar SV, Dispenzieri A. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood. 2012 May 24; 119(21):4860-7. Epub 2012 Apr 13.
    View PubMed
  22. Jiang L, Malik S, Litzow M, Gastineau D, Micallef I, Roy V, Solberg L, Zubair AC. Hematopoietic stem cells from poor and good mobilizers are qualitatively equivalent. Transfusion. 2012 Mar; 52(3):542-8. Epub 2011 Aug 09.
    View PubMed
  23. Gertz MA, Buadi FK, Hayman SR, Dingli D, Dispenzieri A, Greipp PR, Kumar SK, Lacy MQ, Lust JA, Leung N, Rajkumar SV, Russell SJ, Zeldenrust SR, Mikhael JR, Roy V, Kyle RA. Immunoglobulin D amyloidosis: a distinct entity. Blood. 2012 Jan 5; 119(1):44-8. Epub 2011 Nov 07.
    View PubMed
  24. Vishnu P, Roy V, Paulsen A, Zubair AC. Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion. 2012 Jan; 52(1):55-62. Epub 2011 Jun 09.
    View PubMed
  25. Roy V. Autologous stem cell transplant for Al amyloidosis. Bone Marrow Res. 2012; 2012:238961. Epub 2012 May 16.
    View PubMed
  26. Vogl DT, Wang T, Perez WS, Stadtmauer EA, Heitjan DF, Lazarus HM, Kyle RA, Kamble R, Weisdorf D, Roy V, Gibson J, Ballen K, Holmberg L, Bashey A, McCarthy PL, Freytes C, Maharaj D, Maiolino A, Vesole D, Hari P. Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1765-74. Epub 2011 May 11.
    View PubMed
  27. Reinholz MM, Kitzmann KA, Tenner K, Hillman D, Dueck AC, Hobday TJ, Northfelt DW, Moreno-Aspitia A, Roy V, LaPlant B, Allred JB, Stella PJ, Lingle WL, Perez EA. Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437. Clin Cancer Res. 2011 Nov 15; 17(22):7183-93. Epub 2011 Oct 05.
    View PubMed
  28. Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Stewart AK, Laumann K, Mandrekar SJ, Reeder C, Rajkumar SV, Mikhael JR. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011 Sep 15; 118(11):2970-5. Epub 2011 Jun 20.
    View PubMed
  29. Short KD, Rajkumar SV, Larson D, Buadi F, Hayman S, Dispenzieri A, Gertz M, Kumar S, Mikhael J, Roy V, Kyle RA, Lacy MQ. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia. 2011 Jun; 25(6):906-8. Epub 2011 Feb 25.
    View PubMed
  30. Adkisson CD, Vallow LA, Kowalchik K, McNeil R, Hines S, Deperi E, Moreno A, Roy V, Perez EA, McLaughlin SA. Patient age and preoperative breast MRI in women with breast cancer: biopsy and surgical implications. Ann Surg Oncol. 2011 Jun; 18(6):1678-83. Epub 2011 Jan 05.
    View PubMed
  31. Kapoor P, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Dingli D, Mikhael JR, Roy V, Kyle RA, Greipp PR, Kumar S, Mandrekar SJ. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia. 2011 Apr; 25(4):689-96. Epub 2011 Jan 14.
    View PubMed
  32. Vishnu P, Roy V. Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer. Breast Cancer (Auckl). 2011; 5:53-65. Epub 2011 Apr 13.
    View PubMed
  33. Reece DE, Vesole DH, Shrestha S, Zhang MJ, Perez WS, Dispenzieri A, Milone GA, Abidi M, Atkins H, Bashey A, Bredeson CN, Boza WB, Freytes CO, Gale RP, Gajewski JL, Gibson J, Hale GA, Kumar S, Kyle RA, Lazarus HM, McCarthy PL, Pavlovsky S, Roy V, Weisdorf DJ, Wiernik PH, Hari PN. Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study. Clin Lymphoma Myeloma Leuk. 2010 Dec; 10(6):458-63.
    View PubMed
  34. Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV, Buadi F. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010 Nov; 24(11):1934-9. Epub 2010 Sep 09.
    View PubMed
  35. Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, Bergsagel PL, Buadi FK, Colgan JP, Dingli D, Dispenzieri A, Greipp PR, Habermann TM, Hayman SR, Inwards DJ, Johnston PB, Kumar SK, Lacy MQ, Lust JA, Markovic SN, Micallef IN, Nowakowski GS, Porrata LF, Roy V, Russell SJ, Short KE, Stewart AK, Thompson CA, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Gertz MA. Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc. 2010 Sep; 85(9):824-33. Epub 2010 Aug 11.
    View PubMed
  36. Gay F, Rajkumar SV, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ, Chen-Kiang S, Roy V, Jayabalan DS, Lust JA, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Niesvizky R. Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol. 2010 Sep; 85(9):664-9.
    View PubMed
  37. Bhatt V, Vendrell N, Nau K, Crumb D, Roy V. Implementation of a standardized protocol for prevention and management of oral mucositis in patients undergoing hematopoietic cell transplantation. J Oncol Pharm Pract. 2010 Sep; 16(3):195-204. Epub 2009 Nov 12.
    View PubMed
  38. Vishnu P, Roy V. nab-paclitaxel: a novel formulation of taxane for treatment of breast cancer. Womens Health (Lond Engl). 2010 Jul; 6(4):495-506.
    View PubMed
  39. Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, Micallef IN, Porrata LF, Ansell SM, Reeder CB, Roy V, Witzig TE. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010 May; 85(5):320-4.
    View PubMed
  40. Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ, Cervantes F, Devine SM, Gale RP, Gupta V, Hahn TE, Hogan WJ, Kroger N, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Schiller G, Schouten HC, Roy V, Wiernik PH, Horowitz MM, Giralt SA, Arora M. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2010 Mar; 16(3):358-67. Epub 2009 Oct 30.
    View PubMed
  41. Gay F, Hayman SR, Lacy MQ, Buadi F, Gertz MA, Kumar S, Dispenzieri A, Mikhael JR, Bergsagel PL, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Rajkumar SV. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood. 2010 Feb 18; 115(7):1343-50. Epub 2009 Dec 11.
    View PubMed
  42. Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Greipp PR, Hayman SR, Kyle RA, Lacy MQ, Lust JA, Reeder CB, Roy V, Russell SJ, Short KE, Stewart AK, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Bergsagel PL. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc. 2009 Dec; 84(12):1095-110.
    View PubMed
  43. Roy V, Perez EA. Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer. Oncologist. 2009 Nov; 14(11):1061-9. Epub 2009 Nov 03.
    View PubMed
  44. Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Kyle RA, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009 Oct 20; 27(30):5008-14. Epub 2009 Aug 31.
    View PubMed
  45. Schaefer EW, Loaiza-Bonilla A, Juckett M, DiPersio JF, Roy V, Slack J, Wu W, Laumann K, Espinoza-Delgado I, Gore SD, Mayo P2C Phase II Consortium. A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica. 2009 Oct; 94(10):1375-82.
    View PubMed
  46. Hari PN, Zhang MJ, Roy V, Perez WS, Bashey A, To LB, Elfenbein G, Freytes CO, Gale RP, Gibson J, Kyle RA, Lazarus HM, McCarthy PL, Milone GA, Pavlovsky S, Reece DE, Schiller G, Vela-Ojeda J, Weisdorf D, Vesole D. Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. Leukemia. 2009 Aug; 23(8):1528-34. Epub 2009 Mar 26.
    View PubMed
  47. Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig TE, Hayman SR, Dispenzieri A, Buadi F, Bergsagel PL, Gertz MA, Dalton RJ, Mikhael JR, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Stewart AK, Kyle RA, Greipp PR, Rajkumar SV. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2009 Jul 16; 114(3):518-21. Epub 2009 Mar 26.
    View PubMed
  48. Roy V, Perez EA. Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways. Breast Cancer Res Treat. 2009 Jul; 116(1):31-8. Epub 2008 Dec 20.
    View PubMed
  49. Amar S, Roy V, Perez EA. Treatment of metastatic breast cancer: looking towards the future. Breast Cancer Res Treat. 2009 Apr; 114(3):413-22. Epub 2008 May 09.
    View PubMed
  50. Roy V, LaPlant BR, Gross GG, Bane CL, Palmieri FM, North Central Cancer Treatment Group. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol. 2009 Mar; 20(3):449-53. Epub 2008 Dec 15.
    View PubMed
  51. Roy V. Artifactual laboratory abnormalities in patients with paraproteinemia. South Med J. 2009 Feb; 102(2):167-70.
    View PubMed
  52. Zubair AC, Grant R, Wu W, Tun H, Rivera C, Moreno-Aspitia A, Joyce M, Roy V, Colon-Otero G, Solberg LA. Platelet count is a sensitive predictor of autologous peripheral blood progenitor cell collection yield in previously treated plasma cell disease patients. Transfusion. 2008 Jun; 48(6):1106-14. Epub 2008 Feb 25.
    View PubMed
  53. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA, Litzow MR, Fonseca R, Roy V, Rajkumar SV, Gertz MA. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007 Sep; 21(9):2035-42. Epub 2007 Jun 21.
    View PubMed
  54. Amar S, Roy V, Perez EA. Letrozole: present and future role in the treatment of breast cancer. Expert Opin Pharmacother. 2007 Aug; 8(12):1965-75.
    View PubMed
  55. Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR, Kumar S, Lacy MQ, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Reeder CB, Roy V, Kyle RA, Rajkumar SV, Fonseca R. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia. 2007 Mar; 21(3):529-34. Epub 2007 Jan 18.
    View PubMed
  56. Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, Kyle RA, Greipp PR, Witzig TE, Reeder CB, Lust JA, Russell SJ, Hayman SR, Roy V, Kumar S, Zeldenrust SR, Dalton RJ, Stewart AK. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc. 2007 Mar; 82(3):323-41.
    View PubMed
  57. Roy A, Roy V. An unusual case of prochlorperazine induced dyskinesia masquerading as stroke. Resident & Staff Physicians. 2007 Feb; 53(2):45-6.
    View PubMed
  58. Roy A, Roy V. Primary systemic amyloidosis. [Turkish]. SENDROM. 2007; 19(1):62-7.
    View PubMed
  59. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi CF, Kyle RA. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006 Aug; 81(8):1047-53.
    View PubMed
  60. Roy A, Roy V. Primary systemic amyloidosis. Early diagnosis and therapy can improve survival rates and quality of life. Postgrad Med. 2006 Jun-Jul; 119(1):93-9.
    View PubMed
  61. Roy V, Perez EA. New therapies in the treatment of breast cancer. Semin Oncol. 2006 Jun; 33(3 Suppl 9):S3-8.
    View PubMed
  62. Valente M, Roy V, Lacy MQ, Dispenzieri A, Gertz MA. Autologous stem cell transplantation and IgM amyloidosis. Leuk Lymphoma. 2006 Jun; 47(6):1006-12.
    View PubMed
  63. Sekhon SS, Roy V. Thrombocytopenia in adults: A practical approach to evaluation and management. South Med J. 2006 May; 99(5):491-8; quiz 499-500, 533.
    View PubMed
  64. Roy V, Perez EA. Adjuvant docetaxel plus doxorubicin and cyclophosphamide increases survival compared with fluorouracil plus doxorubicin and cyclophosphamide in women with operable node-positive breast cancer. Cancer Treat Rev. 2006 Feb; 32(1):55-8. Epub 2006 Jan 19.
    View PubMed
  65. Roy A, Heckman MG, Roy V. Associations between the hospitalist model of care and quality-of-care-related outcomes in patients undergoing hip fracture surgery. Mayo Clin Proc. 2006 Jan; 81(1):28-31.
    View PubMed
  66. Roy A, Roy V. Using beta-blocker to cut perioperative risk in CAD. [Turkish]. SENDROM. 2006; 18(12):42-5.
    View PubMed
  67. Roy A, Roy V. Using beta-blockers to cut perioperative risk in CAD. Cardioprotective strategies for noncardiac surgery. Postgrad Med. 2005 Dec; 118(6):34-6, 41-2.
    View PubMed
  68. Roy A, Gisel JJ, Roy V, Bouras EP. Superior mesenteric artery (Wilkie's) syndrome as a result of cardiac cachexia. J Gen Intern Med. 2005 Oct; 20(10):C3-4.
    View PubMed
  69. Pavletic SZ, Khouri IF, Haagenson M, King RJ, Bierman PJ, Bishop MR, Carston M, Giralt S, Molina A, Copelan EA, Ringden O, Roy V, Ballen K, Adkins DR, McCarthy P, Weisdorf D, Montserrat E, Anasetti C. Unrelated donor marrow transplantation for B-Cell chronic lymphocytic leukemia after using myeloablative conditioning: Results from the center for international blood and marrow transplant research. J Clin Oncol. 2005 Aug 20; 23(24):5788-94.
    View PubMed
  70. Roy V, Perez WS, Eapen M, Marsh JCW, Pasquini M, Pasquini R, Mustafa MM, Bredeson CN. Bone marrow transplantation for Diamond-Blackfan anemia. Biol Blood Marrow Transplant. 2005 Aug; 11(8):600-8.
    View PubMed
  71. Dispenzieri A, Moreno-Aspitia A, Suarez GA, Lacy MQ, Colon-Otero G, Tefferi A, Litzow MR, Roy V, Hogan WJ, Kyle RA, Gertz MA. Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood. 2004 Nov 15; 104(10):3400-7. Epub 2004 Jul 27.
    View PubMed
  72. Whitehead RP, Lew D, Flanigan RC, Weiss GR, Roy V, Glode ML, Dakhil SR, Crawford ED. Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a Southwest Oncology Group study. J Immunother. 2002 Jul-Aug; 25(4):352-8.
    View PubMed
  73. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001 Dec 6; 345(23):1655-9.
    View PubMed
  74. Roy V, Rizvi MA, Vesely SK, George JN. Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes. Bone Marrow Transplant. 2001 Mar; 27(6):641-6.
    View PubMed
  75. Petersdorf SH, Kopecky KJ, Head DR, Boldt DH, Balcerzak SP, Wun T, Roy V, Veith RW, Appelbaum FR. Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study. Leukemia. 2001 Feb; 15(2):208-16.
    View PubMed
  76. Roy V, Ali LI, Carter TH, Selby GB. Successful non-surgical treatment of disseminated polymicrobial fungal infection in a patient with pancytopenia and graft-versus-host disease. J Infect. 2000 Nov; 41(3):273-5.
    View PubMed
  77. Roy V, Ali LI, Selby GB. Routine chest radiography for the evaluation of febrile neutropenic patients after autologous stem cell transplantation. Am J Hematol. 2000 Jul; 64(3):170-4.
    View PubMed
  78. Fisher RI, Dana BW, LeBlanc M, Kjeldsberg C, Forman JD, Unger JM, Balcerzak SP, Gaynor ER, Roy V, Miller T. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol. 2000 May; 18(10):2010-6.
    View PubMed
  79. Abang AM, Takemoto MH, Pham T, Mandanas RA, Roy V, Selby GB, Carter TH. Efficacy and safety of oral granisetron versus i.v. granisetron in patients undergoing peripheral blood progenitor cell and bone marrow transplantation. Anticancer Drugs. 2000 Feb; 11(2):137-42.
    View PubMed
  80. Roy V, Verfaillie CM. Expression and function of cell adhesion molecules on fetal liver, cord blood and bone marrow hematopoietic progenitors: implications for anatomical localization and developmental stage specific regulation of hematopoiesis. Exp Hematol. 1999 Feb; 27(2):302-12.
    View PubMed
  81. Mandanas RA, Carter TH, Epstein RB, Roy V, Selby GB. Marrow and stem cell transplantation in Oklahoma: fifteen years of experience and results. J Okla State Med Assoc. 1998 Sep; 91(6):339-46.
    View PubMed
  82. Roy V, Verfaillie CM. Soluble factor(s) produced by adult bone marrow stroma inhibit in vitro proliferation and differentiation of fetal liver BFU-E by inducing apoptosis. J Clin Invest. 1997 Aug 15; 100(4):912-20.
    View PubMed
  83. Roy V, Ochs L, Weisdorf D. Late infections following allogeneic bone marrow transplantation: suggested strategies for prophylaxis. Leukemia & Lymphoma. 1997 Jun; 26(1-2):1-15.
    View PubMed
  84. Roy V, Miller JS, Verfaillie CM. Phenotypic and functional characterization of committed and primitive myeloid and lymphoid hematopoietic precursors in human fetal liver. Exp Hematol. 1997 May; 25(5):387-94.
    View PubMed
  85. Roy V, Weisdorf D. Mycobacterial infections following bone marrow transplantation: a 20 year retrospective review. Bone Marrow Transplant. 1997 Mar; 19(5):467-70.
    View PubMed
  86. Verfaillie CM, Bhatia R, Miller W, Mortari F, Roy V, Burger S, McCullough J, Stieglbauer K, Dewald G, Heimfeld S, Miller JS, McGlave PB. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients. Blood. 1996 Jun 1; 87(11):4770-9.
    View PubMed
  87. Roy V, Verfaillie CM. Refractory thrombocytopenia due to anti-PLA1 antibodies following autologous peripheral blood stem cell transplantation: case report and review of literature. Bone Marrow Transplant. 1996 Jan; 17(1):115-7.
    View PubMed
  88. Roy V, Veys P, Jackson F, Ryan J, Lowdell M, Newland AC. Adult respiratory syndrome following autologous bone marrow transfusion. Bone Marrow Transplant. 1989 Nov; 4(6):711-2.
    View PubMed
  89. Roy V, Gutteridge CN, Nysenbaum A, Newland AC. Combination chemotherapy with conservative obstetric management in the treatment of pregnant patients with acute myeloblastic leukaemia. Clinical & Laboratory Haematology. 1989; 11(3):171-8.
    View PubMed
  90. Roy V, Tillyer ML, Colvin BT. Acute abdominal pain due to an acquired disorder of coagulation. Br Med J (Clin Res Ed) 1988 May 21; 296(6634):1460.
    View PubMed